Search
for

    GlossaryGranulocyte-Colony Stimulating Factor

    Granulocyte-Colony Stimulating Factor (G-CSF) is a glycoprotein that plays a crucial role in the regulation of hematopoiesis, particularly in the production and differentiation of neutrophil precursors in the bone marrow. Its relevance to hair loss lies in its potential role in promoting hair follicle regeneration and stimulating hair growth, as it has been shown to influence the hair cycle and enhance the proliferation of dermal papilla cells. Key distinguishing characteristics of G-CSF include its ability to mobilize stem cells and its therapeutic use in treating conditions like neutropenia, which may indirectly impact hair health.

    Related Terms

    Learn

    5 / 801 results

    Research

    5 / 942 results

    Community Join

    5 / 1000+ results

      community PP405 - hair stem cell stimulation

      in Research/Science  53 upvotes 2 years ago
      PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

      community Forgotten 'Total Revival' Stack

      in Research/Science  42 upvotes 1 year ago
      Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

      community new way to activate stem cells to make hair grow

       45 upvotes 7 years ago
      Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

      community Riken develops new method for culturing hair follicles

       41 upvotes 8 years ago
      A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.